Summer Newsletter 2020

*|MC:SUBJECT|*
Toxys Newsletter July 2020
View this email in your browser
Toxys logo
Major improvements of the ToxTracker assay now published
Understanding the Mode of Action of genotoxic compounds can provide vital information for regulatory chemical safety dossiers and can be very valuable for AOP and read-across approaches. We recently expanded the ToxTracker genotoxicity assay to ToxTracker ACE and ToxTracker AO to provide mechanistic insight into the hazardous properties of chemicals and pharmaceuticals. ToxTracker ACE classifies aneugenic and clastogenic compounds and improves the overall sensitivity for genotoxicity and ToxTracker AO identifies indirect genotoxicity due to the formation of ROS. Check out our latest publication featuring these major improvements that was published recently in Toxicological Sciences: "Aneugen versus clastogen evaluation and oxidative stress-related mode-of-action assessment of genotoxic compounds using the ToxTracker reporter assay".
New assays and tools 

Every business is adapting to the ongoing COVID-19 pandemic. As for us, COVID-19 provided the opportunity to shift our capacity towards the development of novel in vitro assays. We have applied our expertise in stem cell biology and reporter technologies in the development of ReproTracker, an hiPSC-based biomaker assay that can identify disruption of stem cell differentiation and early embryonic development. Within the field of genotoxicity, we have developed TubulinTracker, a stem-cell based assay which identifies compounds which disrupt microtubuli extending our possibilities for assessing the modes of actions relevant to dossier building in genetic toxicology.

 
ReproTracker
ReproTracker is a state-of-the-art in vitro biomarker assay that visualises a broad spectrum of key events during early embryonic development. The assay can be used to reliably identify the developmental toxicity hazards of new drugs and chemicals. Interested in learning more about ReproTracker? We will be hosting a webinar on 3 September, at 4.00 pm CET on ReproTracker, please save the date and stay tuned for more details!




 
  

TubulinTracker 
TubulinTracker is a new reporter assay that provides further insight into the genotoxicity of compounds with an aneugenic mode-of-action. The assay assesses Tubulin polymerisation dynamics in the context of the cell as well as disruption of cell cycle progression. TubulinTracker can be used as a stand-alone assay or as a followup test of ToxTracker ACE. TubulinTracker will be presented at the 2020 EMGS virtual meeting, on September 15, 2020. Please save the date and register online to join us!


ToxPlot analysis software for ToxTracker
ToxPlot is our unique ToxTracker data analysis tool, which allows for extensive ToxTracker Data analysis, unbiased data interpretation,  automated report generation and secure data storage. It is also possible to download your ToxTracker data into a PROAST-compatible format for quantitative analysis and potency ranking of compounds. The ToxPlot software is in its final stages of development and will be launched later this summer. You can stay updated on all our news at our website or our LinkedIn page
 
News in short

A new state-of-the-art laboratory
Toxys is growing and rapidly expanding its in vitro chemical safety testing services. Recently, Toxys signed an agreement with BioPartner Leiden for its new  laboratory facilities. In spring 2021, Toxys will relocate to the new BioPartner V laboratory building at the Leiden Bio Science Park. In July the highest point in its construction was celebrated.


BioPartner V construction site                                                   Artist impression of BioPartner V 

The BioPartner V laboratory building is a state-of-the-art laboratory facility with flexible labs and offices. The innovative building is constructed from recycled materials and uses natural, eco-friendly materials to provide a sustainable and inspiring working environment. The building is the perfect location for Toxys to expand its modern laboratory facilities, ready for further expansion of its specialized toxicological research services and allowing further growth of the company.

Expanding our team
We recently expanded the Toxys marketing and sales team. Hanna Frykman has joined Toxys as Director BD & Sales and K Pereni Sri Rajitha as our new Marketing Manager. These additions to the BD & Sales team will help us to accelerate our growth and to expand our reach. 

                 
                                                   Hanna Frykman                                       K Pereni Sri Rajitha
                                                Director BD & Sales                                    Marketing Manager

Case study featuring ToxTracker
ToxTracker was included in a recently published case study by the Unilever Safety and Environmental Assurance Centre. The case study featured a hypothetical safety assessment of coumarin in face cream and body lotion, applying the Next-Generation Risk Assessment approach. https://pubmed.ncbi.nlm.nih.gov/32275751/.

Get in contact
Due to COVID-19, meetings in person have become difficult. We are very happy to instead schedule a call or TC's to tell you more about our technologies and services and to hear about your approach and needs in in vitro toxicology. 

Meetings we will attend
Many conferences have been cancelled due to COVID-19. You are invited to join us online on September 15, 2020, for our presentation on TubulinTracker at the 2020 EMGS virtual meeting.

Please contact us if there are any questions: 

Paula van Rossum                          Hanna Frykman                           Ruairi Mac Siomoin
CBO                                                Director BD & Sales                    Japan liaison (Eaolas Biosciences)
p.vanrossum@toxys.com                h.frykman@toxys.com                macsiomoin@eolas-bio.co.jp   
+31 - 71 - 3322475                          +31 - 71 - 3322475                      +81-47-308-2204

Learn more about our unique services
LinkedIn
LinkedIn
Twitter
Twitter
Website
Website
Copyright © 2019, All rights reserved.

Our mailing address is:
info@toxys.com

Please visit our website for more information on our products and services and our privacy policy:
www.toxys.com

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.






This email was sent to *|EMAIL|*
why did I get this?    unsubscribe from this list    update subscription preferences
*|LIST:ADDRESSLINE|*